Home

Articles from Summit Therapeutics

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona on Sunday, September 7, 2025, at 8:15am CET (2:15am ET). This is the second consecutive year ivonescimab has been featured in the WCLC Presidential Symposium.
By Summit Therapeutics · Via Business Wire · August 14, 2025
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the second quarter ended June 30, 2025.
By Summit Therapeutics · Via Business Wire · August 11, 2025